Regulus lays off 60% of staff, halts development

Regulus Therapeutics announced the latest in a string of setbacks on Friday, including cutting 60% of its workforce in a bid to save $20 million annually in a restructuring effort. The news sent shares down more than 50% to $0.36 a share Friday.